Table I.

Clinicopathological characteristics of EGFR/KRAS mutation status and ALK rearrangement in 200 patients.

	EGFR			KRAS			ALK rearrangement
Clinical features	Mutation	WT	P-value	Mutation	WT	P-value	Positive	Negative	P-value
Gender			0.016			0.323			0.663
Male	35	60		11	84		12	83
Female	57	48		7	98		11	94
Age, years			0.478			0.089			0.001
Range	28–76	23–79		50–78	23–79		23–69	28–79
Median	59	57		63	58		47	61
<60	46	60		6	100		20	86
≥60	46	48		12	82		3	91
Smoking status			0.542			0.429			0.810
Yes	26	35		7	54		6	55
No	66	73		11	128		17	122
Tumor size, cm			0.139			0.001			0.564
≤5	80	85		9	156		18	147
>5	12	23		9	26		5	30
LN metastasis			0.257			0.622			0.046
Yes	45	62		11	96		17	90
No	47	46		7	86		6	87
Clinical stage			1.000			1.000			0.076
I+II	45	53		9	89		7	91
III+IV	47	55		9	93		16	86

EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma receptor tyrosine kinase; LN, lymph node.